COVID-19 Induced Cardiomyopathy Successfully Treated with Tocilizumab
Background. Currently, the literature regarding the management of COVID-19 induced cardiomyopathy with reduced ejection fraction is limited. In this case report, we present the first documented case of COVID-19 induced myocardial stunning leading to severely reduced LV systolic function that was rev...
Saved in:
Main Authors: | Ariyon Schreiber, Kalaimani Elango, Christoph Sossou, Sadaf Fakhra, Shabada Asad, Chowdhury Ahsan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Case Reports in Cardiology |
Online Access: | http://dx.doi.org/10.1155/2022/9943937 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients
by: Yong Wang, et al.
Published: (2022-01-01) -
TAFRO Syndrome Mimicking Solid Cancer and Successfully Treated by Tocilizumab: A Case and Literature Review
by: Pei-An Fu, et al.
Published: (2023-10-01) -
Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01) -
Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia
by: Ruth Alex, et al.
Published: (2022-01-01) -
The Success of the Vaccine Policy in Treating Covid-19 in Indonesia
by: DEVIA ANDIANI, et al.
Published: (2023-02-01)